Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

ClinicalTrials.gov ID: NCT06744647

Public ClinicalTrials.gov record NCT06744647. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Study identification

NCT ID: NCT06744647
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Enrollment: 47 participants

Conditions and interventions

Conditions

Interventions

ALXN2030 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 7, 2025 (Actual)
Primary completion: Oct 11, 2027 (Estimated)
Completion: Nov 7, 2028 (Estimated)
Last update posted: Aug 11, 2026

2025 – 2028

United States locations

U.S. sites: 21
U.S. states: 16
U.S. cities: 19

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35249	—
Research Site	Scottsdale	Arizona	85259	—
Research Site	Los Angeles	California	90095	—
Research Site	Orange	California	92868	—
Research Site	Tampa	Florida	33606	—
Research Site	Atlanta	Georgia	30309	—
Research Site	Kansas City	Kansas	66160	—
Research Site	Ann Arbor	Michigan	48109	—
Research Site	Detroit	Michigan	48202	—
Research Site	Livingston	New Jersey	07039	—
Research Site	New York	New York	10021	—
Research Site	New York	New York	10029	—
Research Site	New York	New York	10032	—
Research Site	Durham	North Carolina	27705	—
Research Site	Cincinnati	Ohio	45267	—
Research Site	Philadelphia	Pennsylvania	19140	—
Research Site	Dallas	Texas	75235	—
Research Site	Houston	Texas	77030	—
Research Site	Richmond	Virginia	23298	—
Research Site	Seattle	Washington	98195	—
Research Site	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06744647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06744647 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →